Maintenance therapy for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced (stage III or IV) ovarian, fallopian tube, or primary peritoneal cancer that is high-grade serous, endometrioid grade 2 or higher, or a mix with more than 50% of these types.
- You have a positive test for HRD (a genetic feature that may make PARP inhibitors more effective).
- You finished 6 to 9 cycles of platinum-based chemotherapy (or at least 4 if you couldn't tolerate more), and your cancer is in remission (no evidence of disease, complete response, or partial response).
- You also received bevacizumab with your last 3 cycles of chemotherapy (or at least 2 if you had interval debulking surgery).
- You are in good general health (ECOG performance status 0 or 1) and your organs (kidney, liver, blood counts) are functioning well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
This trial tests two oral medications given after your first round of chemotherapy. The goal is to see if taking these drugs regularly can keep the cancer from coming back.
This trial tests whether adding fluzoparib to bevacizumab can help control ovarian cancer that has returned after earlier PARP inhibitor (PARPi) treatment. It may help shrink tumors or slow the cancer from growing again.
This study tests a new maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have finished their first round of chemo and are showing good response. The goal is to see if this treatment helps delay the cancer from coming back.
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.